Consequently, it is recommended that patients with non-squamous NSCLC and certain squamous cell carcinomas undergo routine screening for specific driver gene mutations, such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) fusion genes, ROS1 fusion genes, RET fusion genes, BRAF gene V600E mutation, MET gene exon 14 skipping mutation, and other pertinent driver genes. The gene discussed is ALK; the disease is squamous cell carcinoma.